Alexion, AstraZeneca Rare Disease Shares Phase 3 Ultomiris Trial Results
BOSTON, Mass., July 27, 2026 Alexion, AstraZeneca Rare Disease announced high-level results from its global Phase 3 clinical program...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, Mass., July 27, 2026 Alexion, AstraZeneca Rare Disease announced high-level results from its global Phase 3 clinical program...
